The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV

References

• Pathai S, Bajillan H, Landay AL, et al. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69(7):833–842. .
   PubMed Web of Science ®Google Scholar
• Calcagno A, Piconi S, Focà E, et al. Role of normalized T-cell subsets in predicting comorbidities in a large cohort of geriatric HIV-infected patients. J Acquir Immune Defic Syndr. 2017;76(3):338–342.
   PubMed Web of Science ®Google Scholar
• Livio F, Deutschmann E, Moffa G, et al. Analysis of inappropriate prescribing in elderly patients of the swiss HIV cohort study reveals gender inequity. J Antimicrob Chemother. 2021;76(3):758–764.
   PubMed Web of Science ®Google Scholar
• López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, et al., Potentially inappropriate medications in older adults living with HIV. HIV Med. 21(8): 541–546. 2020. .
   PubMed Web of Science ®Google Scholar
• Jourjy J, Dahl K, Huesgen E. Antiretroviral treatment efficacy and safety in older HIV-infected adults. Pharmacotherapy. 2015;35(12):1140–1151.
   PubMed Web of Science ®Google Scholar
• Loste C, Moltó J, Pérez-Álvarez N, et al. Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern? Br J Clin Pharmacol. 2020 August 27;87(3):1310–1317.
   PubMed Web of Science ®Google Scholar
• Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–184.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
   PubMed Web of Science ®Google Scholar
• De Francesco D, Underwood J, Bagkeris E, et al. Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. AIDS. 2019;33(12):1871–1880.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7(5):e37563.
   PubMed Web of Science ®Google Scholar
• Williams GR, Deal AM, Shachar SS, et al. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol. 2018;81(2):413–417.
   PubMed Web of Science ®Google Scholar
• Erdő F, Krajcsi P. Age-related functional and expressional changes in efflux pathways at the blood-brain barrier. Front Aging Neurosci. 2019;11:196.
   PubMed Web of Science ®Google Scholar
• Billington S, Salphati L, Hop CECA, et al. Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics. Clin Pharmacol Ther. 2019;106(1):228–237.
   PubMed Web of Science ®Google Scholar
• Ferrara M, Bumpus NN, Ma Q, et al. Antiretroviral drug concentrations in brain tissue of adult decedents. AIDS. 2020;34(13):1907–1914.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Atzori C, Romito A, et al. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. J Neurovirol. 2016;22(1):88–92.
   PubMed Web of Science ®Google Scholar
• Croteau D, Letendre S, Best B, et al. Older age is associated with higher ARV concentrations in CSF in HIV + individuals. WA, USA: Seattle; 2012.
   Google Scholar
• Calcagno A, Moltó J, Borghetti A, et al. Older age is associated with higher dolutegravir exposure in plasma and cerebrospinal fluid of people living with HIV. Clin Pharmacokinet. 2021;60(1):103–109.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: Proposal from the joint committee of Japan gerontological society and the Japan geriatrics society. Geriatr Gerontol Int. 2017;17(7):1045–1047.
   PubMed Web of Science ®Google Scholar
• Cooper JK, Gardner C. Effect of aging on serum albumin. J Am Geriatr Soc. 1989;37(11):1039–1042.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Cusato J, D’Avolio A, et al. Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs. Clin Pharmacokinet. 2017;56(4):355–369.
   PubMed Web of Science ®Google Scholar
• Xu Y-J, Wang Y, Lu Y-F, et al. Age-associated differences in transporter gene expression in kidneys of male rats. Mol Med Rep. 2017;15(1):474–482.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Francis O, Cottrell M, et al. Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy. Antivir Ther. 2016;21(5):441–445.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. European AIDS Clinical Society Guidelines version 10.0. 2019. [cited 2021 Feb 24]. Available from: https://www.eacsociety.org/files/guidelines-10.0_final_2_2.pdf
   Google Scholar
• De Sousa Mendes M, Chetty M. Are standard doses of renally-excreted antiretrovirals in older patients appropriate: A PBPK study comparing exposures in the elderly population with those in renal impairment. Drugs R D. 2019;19(4):339–350.
   PubMed Web of Science ®Google Scholar
• Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. The veterans administration cooperative studies group. Clin Pharmacol Ther. 1990;48(2):161–167.
   PubMedGoogle Scholar
• Zhou XJ, Sheiner LB, D’Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS clinical trials group protocol 241 investigators. Antimicrob Agents Chemother. 1999;43(1):121–128.
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Hussey EK, et al. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother. 1999;43(12):3025–3029.
   PubMed Web of Science ®Google Scholar
• Valade E, Tréluyer J-M, Illamola SM, et al. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study. Antimicrob Agents Chemother. 2015;59(11):6800–6806.
   PubMed Web of Science ®Google Scholar
• Valade E, Tréluyer J-M, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother. 2014;58(4):2256–2261.
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The data-collection on adverse effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214–223.
   PubMed Web of Science ®Google Scholar
• Collado-Diaz V, Andujar I, Sanchez-Lopez A, et al. Abacavir induces arterial thrombosis in a murine model. J Infect Dis. 2018;218(2):228–233.
   PubMed Web of Science ®Google Scholar
• McDowell JA, Lou Y, Symonds WS, et al. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44(8):2061–2067.
   PubMed Web of Science ®Google Scholar
• Weller S, Radomski KM, Lou Y, et al. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2000;44(8):2052–2060.
   PubMed Web of Science ®Google Scholar
• Jullien V, Tréluyer J-M, Rey E, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49(8):3361–3366.
   PubMed Web of Science ®Google Scholar
• Punyawudho B, Thammajaruk N, Thongpeang P, et al. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. Int J Clin Pharmacol Ther. 2015;53(11):947–954.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? Pharmacogenomics. 2016;17(6):531–534.
   PubMed Web of Science ®Google Scholar
• Rungtivasuwan K, Avihingsanon A, Thammajaruk N, et al. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Pharmacogenomics. 2017;18(16):1481–1490.
   PubMed Web of Science ®Google Scholar
• Bednasz CJ, Venuto CS, Ma Q, et al. Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS clinical trials group study A5202. Antimicrob Agents Chemother. 2019;63(4). DOI:10.1128/AAC.01638-18
   PubMed Web of Science ®Google Scholar
• Calcagno A, Cusato J, Marinaro L, et al. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. AIDS. 2016;30(6):915–920.
   PubMed Web of Science ®Google Scholar
• Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS. 2014;28(1):59–66.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Cusato J, Marinaro L, et al. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. Pharmacogenomics J. 2015 October 6;16(6):514–518.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Fordyce M, Garner W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60(9):5135–5140.
   PubMed Web of Science ®Google Scholar
• Winston A, Jose S, Gibbons S, et al., Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 68(6): 1354–1359. 2013. .
   PubMed Web of Science ®Google Scholar
• Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73(1):20–30.
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, Huitema ADR, Yalvaç Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet. 2005;44(8):849–861.
   PubMed Web of Science ®Google Scholar
• Nyakutira C, Röshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357–365.
   PubMed Web of Science ®Google Scholar
• Cusato J, Tomasello C, Simiele M, et al. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016;47(2):117–123.
   PubMed Web of Science ®Google Scholar
• De Maat MMR, Huitema ADR, Mulder JW, et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002;54(4):378–385.
   PubMed Web of Science ®Google Scholar
• Schipani A, Wyen C, Mahungu T, et al. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother. 2011;66(6):1332–1339.
   PubMed Web of Science ®Google Scholar
• Mustafa S, Yusuf WNW, Woillard JB, et al. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. Eur J Clin Pharmacol. 2016;72(7):831–838.
   PubMed Web of Science ®Google Scholar
• Behm MO, Yee KL, Fan L, et al. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antivir Ther. 2017;22(4):337–344.
   PubMed Web of Science ®Google Scholar
• Yee KL, Ouerdani A, Claussen A, et al. Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1. Antimicrob Agents Chemother. 2019;63(4). DOI:10.1128/AAC.02502-18
   Web of Science ®Google Scholar
• Stader F, Courlet P, Kinvig H, et al., Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. Br J Clin Pharmacol. 87(2): 458–470. 2021. .
   PubMed Web of Science ®Google Scholar
• Van Der Leur MR, Burger DM, La Porte CJL, et al. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006;28(5):650–653.
   PubMed Web of Science ®Google Scholar
• Wang K, D’Argenio DZ, Acosta EP, et al. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clin Pharmacokinet. 2014;53(4):361–371.
   PubMed Web of Science ®Google Scholar
• Moltó J, Barbanoj MJ, Miranda C, et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet. 2008;47(10):681–692.
   PubMed Web of Science ®Google Scholar
• López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, et al. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. Ther Drug Monit. 2011;33(5):573–582.
   PubMed Web of Science ®Google Scholar
• Crommentuyn KML, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60(4):378–389.
   PubMed Web of Science ®Google Scholar
• Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther. 2008;84(1):75–82.
   PubMed Web of Science ®Google Scholar
• Crawford KW, Spritzler J, Kalayjian RC, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010;26(6):635–643.
   PubMed Web of Science ®Google Scholar
• Moltó J, Estévez JA, Miranda C, et al. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. Br J Clin Pharmacol. 2016;82(6):1528–1538.
   PubMed Web of Science ®Google Scholar
• Schipani A, Dickinson L, Boffito M, et al. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr. 2013;62(1):60–66.
   PubMed Web of Science ®Google Scholar
• Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50(11):3801–3808.
   PubMed Web of Science ®Google Scholar
• Arab-Alameddine M, Lubomirov R, Fayet-Mello A, et al. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. J Antimicrob Chemother. 2014;69(9):2489–2498.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Kerr SJ, Punyawudho B, et al. Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29(12):1541–1546.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Van Der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009;85(4):402–408.
   PubMed Web of Science ®Google Scholar
• Kile DA, MaWhinney S, Aquilante CL, et al. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012;28(10):1227–1234.
   PubMed Web of Science ®Google Scholar
• Solas C, Gagnieu M-C, Ravaux I, et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit. 2008;30(6):670–673.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Chen J, Cottrell M, et al. Population pharmacokinetics modeling of unbound efavirenz, atazanavir, and ritonavir in HIV-infected subjects with aging biomarkers. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):128–135.
   PubMedGoogle Scholar
• Barrail-Tran A, Mentré F, Cosson C, et al. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother. 2010;54(2):614–619.
   PubMed Web of Science ®Google Scholar
• Dickinson L, Jackson A, Garvey L, et al. Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients. J Int AIDS Soc. 2010;13(Suppl 4):184.
   Google Scholar
• Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987.
   PubMedGoogle Scholar
• Moltó J, Xinarianos G, Miranda C, et al. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet. 2013;52(7):543–553.
   PubMed Web of Science ®Google Scholar
• Daskapan A, Tran QTD, Cattaneo D, et al. Darunavir population pharmacokinetic model based on HIV outpatient data. Ther Drug Monit. 2019;41(1):59–65.
   PubMed Web of Science ®Google Scholar
• Stillemans G, Belkhir L, Vandercam B, et al. Exploration of reduced doses and short-cycle therapy for darunavir/cobicistat in patients with HIV using population pharmacokinetic modeling and simulations. Clin Pharmacokinet. 2021;60(2):177–189.
   PubMed Web of Science ®Google Scholar
• Daskapan A, Stienstra Y, Kosterink JGW, et al. Risk factors contributing to a low darunavir plasma concentration. Br J Clin Pharmacol. 2018;84(3):456–461.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Magistrelli E, et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med. 2017;18(7):474–481.
   PubMed Web of Science ®Google Scholar
• Courlet P, Stader F, Guidi M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2020;34(1):103–108.
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Londero A, Della Siega P, et al. Comparative population pharmacokinetics of darunavir in SARS-CoV-2 patients vs. HIV patients: The role of interleukin-6. Clin Pharmacokinet. 2020;59(10):1251–1260.
   PubMed Web of Science ®Google Scholar
• Machavaram KK, Almond LM, Rostami-Hodjegan A, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94(2):260–268.
   PubMed Web of Science ®Google Scholar
• Molanaei H, Qureshi AR, Heimbürger O, et al. Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. BMC Pharmacol Toxicol. 2018;19(1). DOI:10.1186/s40360-018-0221-6
   PubMedGoogle Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–740.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Ng DK, Jacobson LP, et al. Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis. 2017;215(2):228–237.
   PubMed Web of Science ®Google Scholar
• Hubbard RE, O’Mahony MS, Savva GM, et al. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9b):3103–3109.
   PubMed Web of Science ®Google Scholar
• Calcagno A, D’Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. Expert Opin Drug Metab Toxicol. 2015;11(7):1167–1176.
   PubMed Web of Science ®Google Scholar
• Vera JH, Jackson A, Dickinson L, et al. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials. 2015;16(1):39–42.
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Havens JP, Podany AT, et al. HIV-1 integrase inhibitors: A comparative review of efficacy and safety. Drugs. 2020;80(16):1649–1676.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Gordi T, Zhong L, et al. Population pharmacokinetics of boosted-elvitegravir in HIV-infected patients. J Clin Pharmacol. 9 October 2015;56(6):723–732.
   PubMed Web of Science ®Google Scholar
• Barceló C, Gaspar F, Aouri M, et al. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. J Antimicrob Chemother. 2016;71(7):1933–1942.
   PubMed Web of Science ®Google Scholar
• FDA. Clinical Pharmacology and Biopharmaceutics Review. 2014.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203094Orig1Orig2s000ClinPharmR.pdf (cited 2021 Feb 23).
   Google Scholar
• Bollen P, Reiss P, Schapiro J, et al. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf. 2015;14(9):1457–1472.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Madeddu G, Gulminetti R, et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017;31(3):455–457.
   PubMed Web of Science ®Google Scholar
• Greenberg L, Ryom L, Wandeler G, et al. Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting. J Acquir Immune Defic Syndr. 2020;83(3):240–250.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hayes S, Sadler BM, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80(3):502–514.
   PubMed Web of Science ®Google Scholar
• Parant F, Miailhes P, Brunel F, et al. Dolutegravir population pharmacokinetics in a real-life cohort of people living with HIV infection: A covariate analysis. Ther Drug Monit. 2019;41(4):444–451.
   PubMed Web of Science ®Google Scholar
• Barcelo C, Aouri M, Courlet P, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9):2690–2697.
   PubMed Web of Science ®Google Scholar
• Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68(1):87–95.
   PubMed Web of Science ®Google Scholar
• Parant F, Miailhes P, Brunel F, et al. Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring. Curr Drug Saf. 16 Published Online First: January 2018;13(1):69–71.
   PubMed Web of Science ®Google Scholar
• Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622.
   PubMedGoogle Scholar
• Borghetti A, Calcagno A, Lombardi F, et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74(4):1035–1043.
   PubMed Web of Science ®Google Scholar
• Podany AT, Scarsi KK, Pham MM, et al. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: An updated review. Clin Pharmacokinet. 2020;59(9):1085–1107.
   PubMed Web of Science ®Google Scholar
• Trezza C, Ford SL, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–245.
   PubMed Web of Science ®Google Scholar
• Han K, Patel P, Baker M, et al. Population pharmacokinetics of cabotegravir in healthy adult subjects and HIV-1 infected patients following administration of oral tablet and long-acting intramuscular injection. the Netherlands: Amsterdam; 2018.
   Google Scholar
• Chan PLS, Weatherley B, McFadyen L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol. 2008;65(Suppl 1):76–85.
   PubMedGoogle Scholar
• Okoli C, Siccardi M, Thomas-William S, et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother. 2012;67(3):671–674.
   PubMed Web of Science ®Google Scholar
• Siccardi M, D’Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics. 2010;20(12):759–765.
   PubMed Web of Science ®Google Scholar
• Blanco J-R, Arroyo-Manzano D, Rojas-Liévano JF, et al. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age. AIDS Res Hum Retroviruses. 2015;31(9):893–897.
   PubMed Web of Science ®Google Scholar
• Magee M, Slater J, Mannino F, et al. Effect of renal and hepatic impairment on the pharmacokinetics of temsavir, the active moiety of fostemsavir. J Clin Pharmacol. 2020 December 28. Published Online First:. 10.1002/jcph.1810
   PubMed Web of Science ®Google Scholar
• Rajoli RKR, Back DJ, Rannard S, et al. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin Pharmacokinet. 2015;54(6):639–650.
   PubMed Web of Science ®Google Scholar
• Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175–186.
   PubMed Web of Science ®Google Scholar
• Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005;77(6):515–528.
   PubMed Web of Science ®Google Scholar
• Yang W, Xiao Q, Wang D, et al. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results. Xenobiotica. 2017;47(2):133–143.
   PubMed Web of Science ®Google Scholar
• Su B, Yao C, Zhao Q-X, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919–2927.
   PubMed Web of Science ®Google Scholar
• Blair HA. Ibalizumab: A review in multidrug-resistant HIV-1 infection. Drugs. 2020;80(2):189–196.
   PubMed Web of Science ®Google Scholar
• Gathe JC, Hardwicke RL, Garcia F, et al. Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: A phase 2a study. J Acquir Immune Defic Syndr. 2021;86(4):482–489.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450–457.
   PubMed Web of Science ®Google Scholar
• Mayer PR, Brown CH, Carter RA, et al. Intramuscular tobramycin pharmacokinetics in geriatric patients. Drug Intell Clin Pharm. 1986;20(7–8):611–615.
   PubMedGoogle Scholar
• Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–e481.
   PubMed Web of Science ®Google Scholar
• Patel P, Ford SL, Crauwels H, et al. 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infect Dis. 2019;6\(Suppl 2):S865-S866. Published 2019 Oct 23. doi:10.1093/ofid/ofz360.2173
   Google Scholar